A week after US-FDA gave emergency use authorization for a booster dose for Pfizer and Moderna mRNA-based Covid-19 vaccine, the third most widely administered vaccine manufacturer Johnson & Johnson provided reported data on the response of a booster dose. The update was highly sought by people who had received the single-shot dose of the J&J vaccine, especially when other companies were preparing to offer a booster shot. Based on an update released by the company on Wednesday, the Booster doses of the J&J one-shot coronavirus vaccine generated a large spike in antibodies against the Coronavirus.
Johnson & Johnson Covid-19 Vaccine Booster Shot Promises A Strong Antibody
According to a statement released by the company on Wednesday, “New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson COVID-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination”. This update is from two Phase 2 trials conducted by the company in the United States and Europe, where more than 2000 or so people received a booster dose of the J&J vaccine six months after receiving the first shot of the J&J vaccine.
According to an update by Dr. Mathai Mammen, the R&D head at Janssen, the pharmaceutical arm of Johnson and Johnson, the first single shot of the J&J vaccine is durable and persistent for close to eight months after administering the vaccine and the booster dose further enhances the antibody response in people who have already taken the J&J vaccine previously. He added that the company is in talks with the FDA and discussions are in progress to have a potential strategy for giving the booster shot of the J&J vaccine eight months after receiving the primary J&J Covid vaccine.
According to data released by the CDC close to 14 million Americans have been administered Johnson and Johnson’s single-shot Covid vaccine since February 2021 when the dose was approved for emergency use.
Some studies conducted in South Africa show that the J&J vaccine holds up against the deadly delta variant of the coronavirus as well.
The Johnson & Johnson vaccine is completely different from the mRNA vaccines of Pfizer and Moderna. In these two vaccines, messenger RNA, or what is popularly known as mRNA is encased in lipid particles and sent to the body to generate an immune response. In contrast, the J&J single-dose vaccine uses a crippled common cold virus called an adenovirus to enable the body to generate an immune response.
Some theoreticians believed that a booster dose of the J&J vaccine may not be effective since the new dose could neutralize antibodies. However, the J&J findings show that administering a booster dose of the same kind gave rise to binding antibodies unlike neutralizing antibodies. Binding antibodies bind or attach to the virus and alert our immune system of the presence of the virus so that the immune system sends white blood cells to destroy the virus. The encouraging results reported by the company on booster dose have put all these concerns to rest.